Change of Adviser and Broker

RNS Number : 3518U

Oxford Biomedica PLC

14 October 2010

 

Change of Adviser and Broker

Oxford, UK - 14 October 2010: Oxford BioMedica ("the Company") (LSE: OXB), a leading gene therapy company, today announces that it has appointed Singer Capital Markets Limited as its corporate broker and financial adviser with immediate effect.

-Ends-

For further information, please contact:
Oxford BioMedica plc: John Dawson, Chief Executive Officer Andrew Wood, Chief Financial Officer	Tel: [phone]
Singer Capital Markets Limited: Shaun Dobson Claes Spång	Tel: [phone]

 

Notes to editors

1. Oxford BioMedica^®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient gene delivery system (LentiVector^®), which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline and its partners include sanofi-aventis, Sigma-Aldrich and Pfizer.  Further information is available at www.oxfordbiomedica.co.uk.

 

END

 

 

APPGGGAWUUPUGAW